CytomX Therapeutics (CTMX) EBT Margin (2014 - 2026)
CytomX Therapeutics posted quarterly EBT Margin of 177.32% for Q1 2026, down 22364.0% year-on-year from N/an in Q1 2025, and up 95.56% on a QoQ basis from 3990.35% in Q4 2025.
CytomX Therapeutics (CTMX) has 13 years of EBT Margin data on file, last reported at 177.32% in Q1 2026.
- For the quarter ending Q1 2026, EBT Margin fell 22364.0% year-over-year to 177.32%; the trailing twelve-month figure through Mar 2026 stood at 165.74% (down 19409.0% YoY), and the FY2025 full-year result was 22.48%, down 4572.0% from the prior year.
- EBT Margin for Q1 2026 stood at 177.32%, up from 3990.35% in the prior quarter.
- Across five years, EBT Margin topped out at 49.72% in Q4 2024 and bottomed at 3990.35% in Q4 2025.
- The 5-year median for EBT Margin is 14.09% (2023), against an average of 303.63%.
- The widest annual swing landed in 2023, when EBT Margin jumped 33968 bps; it then tumbled 404006 bps in 2025.
- A 5-year view of EBT Margin shows it stood at 43.61% in 2022, then jumped by 116 bps to 7.16% in 2023, then jumped by 594 bps to 49.72% in 2024, then sank by 8126 bps to 3990.35% in 2025, then soared by 96 bps to 177.32% in 2026.
- The last three EBT Margin figures came in at 177.32% (Q1 2026), 3990.35% (Q4 2025), and 237.65% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -6.40% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 41.95% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 23.05% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 18.99% |
| 10 | CytomX Therapeutics | 638.18 Mn | 291.48 Mn | - | -177.32% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -177.32% |
| Dec 31, 2025 | -3,990.35% |
| Sep 30, 2025 | -237.65% |
| Jun 30, 2025 | -0.49% |
| Mar 31, 2025 | 46.32% |
| Dec 31, 2024 | 49.72% |
| Sep 30, 2024 | 17.34% |
| Jun 30, 2024 | -25.81% |
| Mar 31, 2024 | 33.38% |
| Dec 31, 2023 | 7.16% |
| Sep 30, 2023 | 22.04% |
| Jun 30, 2023 | -4.40% |
| Mar 31, 2023 | -14.09% |
| Dec 31, 2022 | -43.61% |
| Sep 30, 2022 | -260.73% |
| Jun 30, 2022 | -229.49% |
| Mar 31, 2022 | -353.77% |
| Dec 31, 2021 | -312.82% |
| Sep 30, 2021 | -337.16% |
| Jun 30, 2021 | -303.99% |
| Mar 31, 2021 | -284.59% |
| Dec 31, 2020 | -339.02% |
| Sep 30, 2020 | -335.28% |
| Jun 30, 2020 | -362.03% |
| Mar 31, 2020 | -16.56% |
| Dec 31, 2019 | -802.80% |
| Sep 30, 2019 | -221.24% |
| Jun 30, 2019 | -321.31% |
| Mar 31, 2019 | -81.21% |
| Dec 31, 2018 | -203.30% |
| Sep 30, 2018 | -167.31% |
| Jun 30, 2018 | -117.74% |
| Mar 31, 2018 | -101.49% |
| Dec 31, 2017 | 0.37% |
| Sep 30, 2017 | -42.52% |
| Jun 30, 2017 | -287.82% |
| Mar 31, 2017 | -70.87% |
| Dec 31, 2016 | -224.15% |
| Sep 30, 2016 | -424.46% |
| Jun 30, 2016 | -458.08% |
| Mar 31, 2016 | -720.92% |
| Dec 31, 2015 | -577.72% |
| Sep 30, 2015 | -612.02% |
| Jun 30, 2015 | -283.95% |
| Mar 31, 2015 | -356.54% |
| Dec 31, 2014 | -256.69% |
| Sep 30, 2014 | -187.42% |